Literature DB >> 16685444

Specific immune recognition of pancreatic carcinoma by patient-derived CD4 and CD8 T cells and its improvement by interferon-gamma.

F H Schmitz-Winnenthal1, L V Galindo Escobedo, P Beckhove, V Schirrmacher, M Bucur, Y Ziouta, C Volk, B Schmied, M Koch, D Antolovic, J Weitz, M W Büchler, K Z'Graggen.   

Abstract

Pancreatic carcinoma is a very aggressive disease and little is known about its immunobiology. We here describe the presence in pancreatic cancer patients of spontaneously induced functional CD4 and CD8 memory/effector T cells reactive to autologous tumor cells or to the pancreatic cancer associated antigen, MUC-1. Such specific cells were present in the bone marrow or peripheral blood of most of the 23 tested patients. Low dose stimulation of primary cultures of pancreatic cancer cells with 500 IU/ml IFN-gamma for 72 h enhanced HLA-I expression and induced the de novo expression of HLA-II molecules. This led to a much better immune recognition by autologous HLA-I restricted and purified CD8 T cells and allowed tumor cell recognition by HLA-II restricted purified CD4 T-helper cells. Thus, interferon-gamma appears to be a useful adjuvant cytokine to enhance the immunogenicity of a patients' tumor cells and their recognition by tumor reactive immune cells.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16685444     DOI: 10.3892/ijo.28.6.1419

Source DB:  PubMed          Journal:  Int J Oncol        ISSN: 1019-6439            Impact factor:   5.650


  10 in total

1.  MHC class II expression in pancreatic tumors: a link to intratumoral inflammation.

Authors:  Matthias M Gaida; Thilo Welsch; Esther Herpel; Darjus F Tschaharganeh; Lars Fischer; Peter Schirmacher; G Maria Hänsch; Frank Bergmann
Journal:  Virchows Arch       Date:  2011-11-27       Impact factor: 4.064

2.  Attenuated Toxoplasma gondii Stimulates Immunity to Pancreatic Cancer by Manipulation of Myeloid Cell Populations.

Authors:  Kiah L Sanders; Barbara A Fox; David J Bzik
Journal:  Cancer Immunol Res       Date:  2015-03-24       Impact factor: 11.151

Review 3.  Myeloid-derived suppressor cells: general characteristics and relevance to clinical management of pancreatic cancer.

Authors:  P Goedegebuure; J B Mitchem; M R Porembka; M C B Tan; B A Belt; A Wang-Gillam; W E Gillanders; W G Hawkins; D C Linehan
Journal:  Curr Cancer Drug Targets       Date:  2011-07       Impact factor: 3.428

4.  Fowlpox-based survivin vaccination for malignant mesothelioma therapy.

Authors:  Pietro Bertino; Maddalena Panigada; Elisa Soprana; Valentina Bianchi; Sabrina Bertilaccio; Francesca Sanvito; Aaron H Rose; Haining Yang; Giovanni Gaudino; Peter R Hoffmann; Antonio Siccardi; Michele Carbone
Journal:  Int J Cancer       Date:  2013-02-25       Impact factor: 7.396

5.  Circulating mesothelin protein and cellular antimesothelin immunity in patients with pancreatic cancer.

Authors:  Fabian Mc Johnston; Marcus C B Tan; Benjamin R Tan; Matthew R Porembka; Elizabeth M Brunt; David C Linehan; Peter O Simon; Stacey Plambeck-Suess; Timothy J Eberlein; Karl Erik Hellstrom; Ingegerd Hellstrom; William G Hawkins; Peter Goedegebuure
Journal:  Clin Cancer Res       Date:  2009-10-20       Impact factor: 12.531

Review 6.  T cells and adoptive immunotherapy: recent developments and future prospects in gastrointestinal oncology.

Authors:  Amedeo Amedei; Elena Niccolai; Mario M D'Elios
Journal:  Clin Dev Immunol       Date:  2011-11-03

7.  Long-peptide vaccination with driver gene mutations in p53 and Kras induces cancer mutation-specific effector as well as regulatory T cell responses.

Authors:  Jasmin Quandt; Christoph Schlude; Michael Bartoschek; Rainer Will; Angel Cid-Arregui; Sebastian Schölch; Christoph Reissfelder; Jürgen Weitz; Martin Schneider; Stefan Wiemann; Frank Momburg; Philipp Beckhove
Journal:  Oncoimmunology       Date:  2018-09-21       Impact factor: 8.110

8.  Proimmunogenic impact of MEK inhibition synergizes with agonist anti-CD40 immunostimulatory antibodies in tumor therapy.

Authors:  Daniel Baumann; Tanja Hägele; Julian Mochayedi; Jennifer Drebant; Caroline Vent; Sven Blobner; Julia Han Noll; Irena Nickel; Corinna Schumacher; Sophie Luise Boos; Aline Sophie Daniel; Susann Wendler; Michael Volkmar; Oliver Strobel; Rienk Offringa
Journal:  Nat Commun       Date:  2020-05-01       Impact factor: 14.919

9.  TGF-β Alters the Proportion of Infiltrating Immune Cells in a Pancreatic Ductal Adenocarcinoma.

Authors:  Kasia Trebska-McGowan; Mehdi Chaib; Marcus A Alvarez; Rita Kansal; Ajeeth K Pingili; David Shibata; Liza Makowski; Evan S Glazer
Journal:  J Gastrointest Surg       Date:  2021-07-14       Impact factor: 3.452

Review 10.  [The ambiguous role of the inflammatory micromilieu in solid tumors].

Authors:  Matthias M Gaida
Journal:  Pathologe       Date:  2020-12       Impact factor: 1.011

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.